[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 6062
1. Baum KJ, Ren R: Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol Oncol; 2008 Jun 05;1:5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, N17 H-Ras did not suppress myelopoiesis in the bone marrow, yet it greatly attenuated BCR/ABL-induced chronic myelogenous leukemia (CML)-like myeloproliferative disease.
  • Most BCR/ABL + N17 H-Ras mice eventually developed pro-B lymphoblastic leukemia/lymphoma (B-ALL).

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2003 May;4(5):373-84 [12728271.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3938-46 [12907435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602 [14699048.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):528-38 [14966562.001]
  • [Cites] J Exp Med. 1976 Jun 1;143(6):1453-63 [178822.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] J Exp Med. 1991 May 1;173(5):1213-25 [1827140.001]
  • [Cites] Cell. 1993 Oct 8;75(1):175-85 [8402896.001]
  • [Cites] EMBO J. 1994 Feb 15;13(4):764-73 [8112292.001]
  • [Cites] Ann N Y Acad Sci. 1994 May 31;716:327-30 [8024205.001]
  • [Cites] J Exp Med. 1995 Jan 1;181(1):307-13 [7807010.001]
  • [Cites] EMBO J. 1995 Jan 16;14(2):276-85 [7835338.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1709-13 [7878045.001]
  • [Cites] Oncogene. 1997 Sep 4;15(10):1151-9 [9294608.001]
  • [Cites] Genes Dev. 1997 Oct 1;11(19):2468-81 [9334313.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):7019-31 [9384581.001]
  • [Cites] Cell. 1998 May 29;93(5):841-50 [9630227.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3780-92 [9808572.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3829-40 [9808576.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6918-28 [10490629.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):172-83 [15719031.001]
  • [Cites] Anal Biochem. 2000 Apr 10;280(1):20-8 [10805516.001]
  • [Cites] Blood. 2000 Jul 15;96(2):664-70 [10887132.001]
  • [Cites] Mol Cell. 2000 Sep;6(3):693-704 [11030348.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):840-53 [11154271.001]
  • [Cites] Mol Cell Biol. 2001 Mar;21(5):1444-52 [11238881.001]
  • [Cites] J Cell Sci. 2001 May;114(Pt 9):1603-8 [11309191.001]
  • [Cites] Oncogene. 2001 Dec 13;20(57):8236-48 [11781838.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2957-68 [11929787.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):479-92 [12124177.001]
  • [Cites] J Cell Biol. 2003 Jan 20;160(2):165-70 [12527752.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):6-13 [12573429.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4572-81 [12458225.001]
  • [Cites] Cancer Treat Res. 2003;115:189-208 [12613198.001]
  • (PMID = 18577264.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA068008; United States / NCI NIH HHS / CA / CA68008
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2438443
  •  go-up   go-down


2. Jo SH, Schatz JH, Acquaviva J, Singh H, Ren R: Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. Blood; 2010 Oct 14;116(15):2759-67
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The closely related family member IRF-8 is a critical regulator of myelopoiesis, which when deleted in mice results in a syndrome highly similar to human chronic myelogenous leukemia.
  • We found that mice deficient in both IRF-4 and IRF-8 develop from a very early age a more aggressive chronic myelogenous leukemia-like disease than mice deficient in IRF-8 alone, correlating with a greater expansion of granulocyte-monocyte progenitors.
  • Although these results demonstrate, for the first time, that IRF-4 can function as tumor suppressor in myeloid cells, interestingly, all mice deficient in both IRF-4 and IRF-8 eventually develop and die of a B-lymphoblastic leukemia/lymphoma.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2005;33(21):6895-905 [16396836.001]
  • [Cites] Blood. 2009 May 7;113(19):4690-701 [19228926.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1396-403 [17971486.001]
  • [Cites] Immunity. 2008 Mar;28(3):335-45 [18280186.001]
  • [Cites] Nature. 2008 Jul 10;454(7201):226-31 [18568025.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3798-806 [18713947.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4274-81 [10590072.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(4):1149-61 [10648600.001]
  • [Cites] Leukemia. 2000 Mar;14(3):449-56 [10720141.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3331-8 [11013272.001]
  • [Cites] Annu Rev Immunol. 2001;19:623-55 [11244049.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3648-50 [11369663.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(19):6369-86 [11533227.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jan;22(1):121-33 [11846983.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jan;22(1):145-52 [11846985.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):137-47 [12110174.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1261-9 [12133947.001]
  • [Cites] Genes Dev. 2003 Jul 15;17(14):1703-8 [12832394.001]
  • [Cites] N Engl J Med. 2003 Oct 9;349(15):1451-64 [14534339.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4547-54 [12933588.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Blood. 2004 May 1;103(9):3480-9 [14656881.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4142-9 [14976051.001]
  • [Cites] Cell. 1996 Oct 18;87(2):307-17 [8861914.001]
  • [Cites] Science. 1997 Jan 24;275(5299):540-3 [8999800.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3829-40 [9808576.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):411-21 [10430629.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2713-22 [10453013.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50874-85 [15371411.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):367-75 [15611260.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2573-81 [15728463.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):172-83 [15719031.001]
  • [Cites] J Exp Med. 2005 Mar 21;201(6):881-90 [15781580.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15989-94 [16236719.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16001-6 [16243976.001]
  • [Cites] Biochem J. 2009 Apr 1;419(1):29-49 [19272022.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):2954-61 [19383829.001]
  • [Cites] Nat Immunol. 2006 Jul;7(7):773-82 [16767092.001]
  • (PMID = 20585039.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL083515; United States / NHLBI NIH HHS / HL / R01HL083515; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Tumor Suppressor Proteins; 0 / interferon regulatory factor-4; 0 / interferon regulatory factor-8
  • [Other-IDs] NLM/ PMC2974585
  •  go-up   go-down


3. Jung SI, Cho HS, Lee CH, Jung BC: A case of adult B lymphoblastic leukemia with ider(9)(q10)t(9;22)(q34;q11.2) and der(19)t(1;19)(q23;p13.3). Korean J Lab Med; 2010 Dec;30(6):585-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of adult B lymphoblastic leukemia with ider(9)(q10)t(9;22)(q34;q11.2) and der(19)t(1;19)(q23;p13.3).
  • In B lymphoblastic leukemia/lymphoma (B-ALL/LBL), t(9;22)(q34;q11.2) and t(1;19)(q23;p13.3) are recurrent cytogenetic abnormalities.
  • This abnormality is specific to precursor B-lymphoid neoplasms, such as B-ALL or B-lymphoid blast phase of CML, and is associated with disease progression or short survival.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157143.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


Advertisement
4. MacDonald DH, Clark I, Naresh KN: The Hammersmith Hospital hematopathology case of the month: paraspinal B lymphoblastic lymphoma – problems in diagnosis and initial indolent behavior. Leuk Lymphoma; 2010 Oct;51(10):1913-9
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Hammersmith Hospital hematopathology case of the month: paraspinal B lymphoblastic lymphoma – problems in diagnosis and initial indolent behavior.
  • Biopsy showed features of a small B-cell lymphoma possibly of follicle center cell origin.
  • Biopsy of the recurrent lesion showed features of B lymphoblastic leukemia/lymphoma.
  • The first biopsy was revisited to demonstrate the lymphoblastic immunophenotype of the lesional cells.
  • [MeSH-major] Leukemic Infiltration / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Thoracic Vertebrae / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858095.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


5. Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, Liu X: Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia; 2008 Feb;22(2):361-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis.
  • In this study, we showed that CAR was expressed on two types of lymphoblastic leukemia cell lines and primary leukemia cells, and that ZD55, a CRAd, exerted a potent antileukemia effect in vitro and in vivo.
  • These data for the first time indicate that MDA-7/IL-24 exerts its antitumor effect on leukemia cells via multiple pathways, and suggest that oncolytic adenoviruses, ZD55 and ZD55-IL-24 could potentially be used against CAR-expressing hematological malignancies such as B-lymphoblastic leukemia/lymphoma and some myeloid leukemia.
  • [MeSH-major] Adenoviridae / genetics. Apoptosis. Interleukins / administration & dosage. Leukemia, B-Cell / therapy. Oncolytic Virotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18046450.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukins; 0 / interleukin-24
  •  go-up   go-down


6. Chen W, Karandikar NJ, McKenna RW, Kroft SH: Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience. Am J Clin Pathol; 2007 Jan;127(1):39-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience.
  • Essentially all cases of precursor B-lymphoblastic leukemia/lymphoma (B-ALL) demonstrate multiple immunophenotypic aberrancies relative to normal maturing B-cell precursors (hematogones).
  • [MeSH-major] B-Lymphocytes / cytology. Burkitt Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145625.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


7. Desouki MM, Post GR, Cherry D, Lazarchick J: PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms. Clin Med Res; 2010 Jul;8(2):84-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PAX-5, a transcription factor expressed throughout B-cell maturation, is detected in most B-cell neoplasms including those that lack expression of mature B-cell markers, such as classical Hodgkin lymphoma (cHL), B-lymphoblastic leukemia and B-cell lymphomas following rituximab therapy.
  • The lack of PAX-5 expression in most CD30-positive non-hematopoietic malignancies (embryonal carcinoma and seminoma) and T-cell lymphomas, such as anaplastic large cell lymphoma (ALCL), suggests that the absence of PAX-5 may be used to confirm non-B-cell lineage.
  • DESIGN: Diagnostic lymph node, decalcified core bone marrow biopsies and tissue sections from 111 archived paraffin-embedded tissue blocks and a tissue lymphoma microarray were immunostained using a monoclonal antibody to PAX-5.
  • RESULTS: Nuclear PAX-5 immunoreactivity was detected in 88% (36/41) of Hodgkin lymphoma, all cases of diffuse large B-cell lymphoma (n=72), small B-cell lymphomas (n=5), B-lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia with B-cell lineage (n=5).
  • PAX-5 was not detected in ALCL (n=22), T-cell lymphoblastic leukemia/lymphoma, mixed phenotype acute leukemia with T-cell lineage (n=5), acute myeloid leukemia (n=4), carcinoid tumors with typical morphology (n=5), melanoma (n=3), and undifferentiated/metastatic tumors (n=8).
  • [MeSH-major] B-Cell-Specific Activator Protein / analysis. Biomarkers, Tumor / analysis. Lymphoma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hodgkin Disease / diagnosis. Humans. Immunohistochemistry. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2001 Sep;114(4):881-3 [11564080.001]
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2335-41 [12613521.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4620-5 [12907641.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):767-77 [14608905.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7399-404 [15492262.001]
  • [Cites] Genomics. 1991 Oct;11(2):424-34 [1685142.001]
  • [Cites] Blood. 1992 Jul 15;80(2):470-7 [1378322.001]
  • [Cites] Genes Dev. 1992 Sep;6(9):1589-607 [1516825.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1308-16 [9694719.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):611-5 [10100713.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jan;129(1):32-8 [15628906.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1542-9 [16056244.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):1010-8 [16648862.001]
  • [Cites] Am J Clin Pathol. 2006 Aug;126(2):235-40 [16891199.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):534-44 [16938666.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1003-8 [17016584.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):798-804 [17050077.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1127-38 [17577776.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):871-7 [17529924.001]
  • [Cites] Lab Invest. 2009 Mar;89(3):301-14 [19139719.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):775-80 [19145202.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):709-14 [16837628.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • (PMID = 20660931.001).
  • [ISSN] 1554-6179
  • [Journal-full-title] Clinical medicine & research
  • [ISO-abbreviation] Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC2910102
  •  go-up   go-down


8. Nishimura H, Akiyama T, Monobe Y, Matsubara K, Igarashi Y, Abe M, Sugihara T, Sadahira Y: Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma. Mod Pathol; 2010 Mar;23(3):439-49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma.
  • In this study, we evaluated sphingosine-1-phosphate receptor 1's suitability as a diagnostic marker for malignant lymphoma by immunostaining formalin-fixed paraffin-embedded sections using a well-defined commercial anti-sphingosine-1-phosphate receptor 1 antibody.
  • Microarray-based immunohistochemistry with tissue samples from 85 lymphoid malignancy cases demonstrated that sphingosine-1-phosphate receptor 1 was expressed on the surface of mantle cell lymphoma cells.
  • Strong expression was observed in all classical mantle cell lymphoma cases involving the lymph node (19 out of 19), gastrointestinal tract (10 out of 10), bone marrow (9 out of 9), and orbita (1 out of 1).
  • One aggressive variant of mantle cell lymphoma displayed a weaker membranous staining than classical mantle cell lymphoma in the lymph node and bone marrow.
  • In a cyclin D1-negative mantle cell lymphoma of the orbita, no conclusive result was obtained.
  • No cases of follicular lymphoma, marginal zone lymphoma, B lymphoblastic leukemia/lymphoma, or Burkitt's lymphoma showed any significant expression, whereas 2 out of 6 chronic lymphocytic leukemia/small lymphocytic lymphomas in bone marrow, 1 out of 3 lymphoplasmacytic lymphomas in the lymph node, and 2 out of 37 diffuse large B-cell lymphomas exhibited staining.
  • A quantitative reverse transcription polymerase chain reaction-based analysis of mantle cell lymphoma lines revealed the sphingosine-1-phosphate receptor 1 mRNA expression level to be well correlated with the results of immunocytochemistry, flow cytometry, and western blotting.
  • Thus, sphingosine-1-phosphate receptor 1 immunohistochemistry may be useful in the histological diagnosis of mantle cell lymphoma with formalin-fixed and paraffin-embedded sections.
  • [MeSH-major] Lymphoma, Mantle-Cell / metabolism. Receptors, Lysosphingolipid / metabolism

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20081804.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCND1 protein, human; 0 / Receptors, Lysosphingolipid; 0 / S1PR1 protein, human; 136601-57-5 / Cyclin D1
  •  go-up   go-down


9. Gross SA, Zhu X, Bao L, Ryder J, Le A, Chen Y, Wang XQ, Irons RD: A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China. Int J Hematol; 2008 Sep;88(2):165-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China.
  • The frequency of non-Hodgkin lymphoma was 87.6% (n = 728) and Hodgkin lymphoma was 12.4% (n = 103).
  • The most prevalent NHL subtypes diagnosed using WHO criteria were diffuse large B cell lymphoma (DLBCL), precursor B lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • Consistent with previous reports, our findings indicate a decrease in the frequency of follicular lymphoma and an increase in T cell neoplasms compared to the West.
  • Precursor T lymphoblastic leukemia/lymphoma, anaplastic large T cell lymphoma, aggressive NK cell leukemia, angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma were prominent subtypes of T cell NHL.
  • [MeSH-major] Asian Continental Ancestry Group / statistics & numerical data. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / ethnology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):143-8 [6381328.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1091-6 [15205204.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1813-9 [8859197.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1151-68 [7858247.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Cancer Lett. 1999 Jan 8;135(1):73-81 [10077224.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):174-81 [8004573.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] Int J Hematol. 2007 Jan;85(1):18-25 [17261497.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1360-4 [17326056.001]
  • [Cites] Hum Pathol. 1987 Sep;18(9):924-8 [3497862.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):323-32 [16280661.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1586-92 [11013375.001]
  • [Cites] Br J Haematol. 1999 Nov;107(2):353-6 [10583224.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2005 Jan;34(1):22-7 [15796877.001]
  • [Cites] Pathol Int. 2002 Jan;52(1):1-12 [11940200.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • (PMID = 18648906.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


10. Dorfman DM, Shahsafaei A: CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms. Am J Clin Pathol; 2010 Nov;134(5):726-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), CD200 is expressed in other B-cell lymphoproliferative disorders, including hairy cell leukemia.
  • In addition, neoplastic cells in classical Hodgkin lymphoma are immunoreactive for CD200.
  • CD200 was previously reported to be expressed in acute myeloid leukemia, and we find that it is also expressed in B-lymphoblastic leukemia/lymphoma.
  • [MeSH-major] Antigens, CD / metabolism. Leukemia, B-Cell / metabolism. Leukemia, Hairy Cell / metabolism. Lymphoma, B-Cell / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959655.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / antigens, CD200
  •  go-up   go-down


11. Rodig SJ, Shahsafaei A, Li B, Dorfman DM: The CD45 isoform B220 identifies select subsets of human B cells and B-cell lymphoproliferative disorders. Hum Pathol; 2005 Jan;36(1):51-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 94 cases of B-cell lymphoproliferative disorders, 33 (35%) were positive for B220 by flow cytometric immunophenotypic analysis, including most cases of marginal zone lymphoma, follicular lymphoma, and lymphoplasmacytic lymphoma.
  • In contrast, all cases of precursor B lymphoblastic leukemia/lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma were negative for B220.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15712182.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / Protein Isoforms; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


12. Ling JY, Sun XF, Yan SL, He LR, Zhen ZJ, Xia Y: [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. Ai Zheng; 2007 Apr;26(4):418-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Diagnosis of lymphocytic leukemia and non-Hodgkin's lymphoma (NHL) is based on bone marrow morphology.
  • This study was to analyze the immunophenotypic characteristics of lymphocytic leukemia and NHL with bone marrow involvement using flow cytometry (FCM).
  • METHODS: Bone marrow specimens from 112 patients with lymphocytic leukemia or NHL with bone marrow involvement were detected by FCM using antibodies of T, B and myeloid cell series.
  • RESULTS: In 45 cases of precursor B lymphoblastic leukemia/lymphoma (B-ALL/LBL), the antigens were mainly CD19, CD10, TdT, CD34, HLA-DR, and CD20.
  • In 32 cases of precursor T lymphoblastic leukemia/lymphoma (T-ALL/LBL), the antigens were mainly CD7, CD5, cytoplasmic (Cy)CD3, TdT, CD34, surface CD3 (sCD3), and HLA-DR.
  • Of the 77 cases of precursor ALL/LBL, 28(36.4%) expressed myeloid-associated antigens, such as CD13 and CD33; 9 (20.0%) cases of B-ALL/LBL coexpressed CD20 and CD34; 28(87.5%) cases of T-ALL/LBL coexpressed cyCD3 and TdT.
  • Among the 35 cases of mature B-cell malignancies, 17 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) mainly expressed CD19, CD20, CD5, HLA-DR, with coexpression of CD19 and CD5; 4 cases of diffuse large B-cell lymphoma (DLBCL) mainly expressed CD19, CD20, CD10, and HLA-DR; 3 cases of Burkitt's lymphoma (BL) mainly expressed CD19, CD10, CD20, and sIgM; 1 case of mantle cell lymphoma (MCL) expressed CD5, CD19, CD20, and HLA-DR.
  • Among the 10 mature T-cell malignancies, 5 cases of unspecialied peripheral T-cell lymphoma (PTCL) mainly expressed sCD3, CD5 and CD7, CD4 or CD8; 1 case of anaplastic large cell lymphoma (ALCL) expressed sCD3 and HLA-DR; 4 cases of NK/T-cell malignancies expressed CD56 and HLA-DR, CD4 or CD8 or CD7.
  • [MeSH-major] Antigens, CD / analysis. Bone Marrow / immunology. Immunophenotyping. Leukemia, Lymphoid / immunology. Lymphoma, Non-Hodgkin / immunology

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430665.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / HLA-DR Antigens
  •  go-up   go-down


13. Luong NV, Kantarjian HM, Faderl SH, Thomas DA, Vu KD: Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL). J Clin Oncol; 2009 May 20;27(15_suppl):7059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL).
  • Although neoplastic diseases are known risk factors for the development of VTE, little is known about the incidence and predisposing factors of VTE among leukemia patients (pts).
  • Further studies should be done in other leukemias to establish guidelines in the prevention and management of VTE in pts with leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Nasr MR, Rosenthal N, Syrbu S: Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. Am J Clin Pathol; 2010 Jan;133(1):41-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
  • The optimal use of transcription factors to determine B-lineage specificity in B-acute lymphoblastic leukemia/lymphoma (B-ALL) has not been fully investigated.
  • We undertook an extensive immunohistochemical study of a panel of B-cell transcription factors in B- and T-ALL and Burkitt lymphoma to evaluate those with the best specificity and sensitivity.
  • Tissue microarrays were constructed from 34 B-ALL, 19 T-ALL, and 30 Burkitt lymphoma samples.
  • Burkitt lymphoma cases were positive for PAX5 (30/30 [100%]), BOB.1 (27/30 [90%]), PU.1 (23/30 [77%]), CD79a (29/30 [97%]), CD22 (14/30 [47%]), CD20 (30/30 [100%]), OCT-2 (23/30 [77%]), and MUM1 (5/30 [17%]).
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Burkitt Lymphoma / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cells, B-Lymphoid / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023257.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / PAX5 protein, human
  •  go-up   go-down


15. Karimi M, Eshghi P: Unusual lymphoblastic leukemia/lymphoma in Eastern Iran. Indian J Pediatr; 2006 Jul;73(7):619-22
MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual lymphoblastic leukemia/lymphoma in Eastern Iran.
  • Lymphoblastic lymphoma-leukemia (LBLL) most commonly presents with mediastinal masses (50-75%), while pleural and pericardial effusion may also be present.
  • Morphologic and flowcytometric evaluation of bone marrow aspiration showed that it was a T cell type acute leukemia which may be due to dissemination of a lymphoblastic lymphoma and considered as a case of lymphoma-leukemia.
  • [MeSH-major] Gingival Hypertrophy / etiology. Jaw Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Child. Humans. Iran. Leukemia, Lymphoid / complications. Leukemia, Lymphoid / diagnosis. Male

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Blood. 1986 Feb;67(2):474-8 [3080041.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1984 Jul;64(1):38-47 [6375764.001]
  • [Cites] Cancer. 1976 Aug;38(2):964-83 [1067894.001]
  • [Cites] Ann Intern Med. 1978 Sep;89(3):415-7 [356693.001]
  • [Cites] Mod Pathol. 1988 Jan;1(1):15-22 [3266334.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Oct;82(4):434-6 [8899783.001]
  • [Cites] Cancer Res. 1983 Sep;43(9):4486-90 [6191861.001]
  • [Cites] J Am Acad Dermatol. 1991 Dec;25(6 Pt 1):1023-31 [1810981.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1993 Jul;29B(3):225-9 [8298427.001]
  • [Cites] Br J Haematol. 1996 Mar;92(3):665-72 [8616033.001]
  • (PMID = 16877858.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


16. Han X, Bueso-Ramos CE: Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias. Am J Clin Pathol; 2007 Apr;127(4):528-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias.
  • Session 4 of the 2005 Society of Hematopathology/European Association for Haematopathology Workshop focused on case presentations of precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (pre-T ALL/LBL) and acute biphenotypic leukemia.
  • An accurate diagnosis of pre-T ALL/LBL and acute biphenotypic leukemia requires a multiparametric approach, including examination of morphologic features, immunophenotype, clinical characteristics, and cytogenetic and molecular findings.
  • [MeSH-major] Biomarkers, Tumor / analysis. Leukemia, Lymphoid / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis


17. Sweetenham JW: Lymphoblastic lymphoma in adults. Curr Hematol Malig Rep; 2006 Dec;1(4):241-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoblastic lymphoma in adults.
  • Understanding of the pathogenesis and biology of precursor T-cell and B-cell neoplasms has advanced significantly with the description of gene expression profiling studies, especially in T-cell disease.
  • Optimal treatment strategies for adult lymphoblastic lymphoma are uncertain, although current evidence supports the use of regimens similar to those used in acute lymphoblastic leukemia, with intensive induction therapy, central nervous system prophylaxis, and prolonged consolidation maintenance therapy.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Leuk Lymphoma. 1994 Oct;15(3-4):291-6 [7866277.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2927-36 [11387366.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):268-74 [14983942.001]
  • [Cites] Ann Intern Med. 1978 Sep;89(3):319-24 [686542.001]
  • [Cites] Leuk Lymphoma. 1999 Dec;36(1-2):101-8 [10613454.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Br J Haematol. 1989 Sep;73(1):82-7 [2803982.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4379-85 [12036865.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] Cancer. 1987 Jul 15;60(2):183-90 [2954631.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2347-57 [6895347.001]
  • [Cites] Ann Oncol. 1995 May;6(5):445-51 [7545428.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1358-65 [8021726.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):57-67 [3510283.001]
  • [Cites] Blood. 2004 Jan 15;103(2):442-50 [14504110.001]
  • [Cites] J Clin Invest. 1985 Jul;76(1):248-53 [2410458.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Ann Oncol. 1990;1(2):141-6 [2078494.001]
  • [Cites] Mol Diagn. 1996 Jun;1(2):139-151 [10330209.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] J Pathol. 1999 Jul;188(3):267-70 [10419594.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):644-6 [1548528.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):619-25 [9681075.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2220-4 [14576732.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] Bone Marrow Transplant. 1992 Jul;10(1):33-8 [1515876.001]
  • [Cites] Cancer. 2002 May 15;94(10):2738-44 [12173345.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):423-9 [14976526.001]
  • [Cites] Leuk Lymphoma. 1996 Nov;23(5-6):577-82 [9031089.001]
  • [Cites] Cancer. 1979 Dec;44(6):1990-9 [389403.001]
  • [Cites] Blood. 1981 Apr;57(4):679-84 [6970598.001]
  • (PMID = 20425319.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


18. Lamvik J, Waage A, Wahl SG, Naess I, Paulsen PQ, Hammerstrøm J: Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004. Haematologica; 2006 Oct;91(10):1428-9
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004.
  • We report a population-based investigation on adult acute precursor B lymphoblastic leukemia, Burkitt's lymphoma and T lymphoblastic lymphoma in a defined geographic area.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


19. Zeng Y, Ni X, Meng WT, Wen Q, Jia YQ: [Inhibitive effect of artesunate on human lymphoblastic leukemia/lymphoma cells]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov;40(6):1038-43
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inhibitive effect of artesunate on human lymphoblastic leukemia/lymphoma cells].
  • OBJECTIVE: To test the effect of Artesunate (ART) on the proliferation of Raji cells, Jurkat cells and acute lymphoblastic leukemia (ALL) primary cells; to determine the synergistic antiproliferation effect between ART and Vincristine (VCR) or Cytarabine(Ara-C) on Raji and Jurkat cells; and to explore the mechanism of ART induced apoptosis of tumor cells in vitro.
  • CONCLUSION: ART alone or combined with chemotherapy drugs could inhibit the proliferation of B/T lymphocytic tumor cell lines as well ALL primary cells in vitro, probably through the mechanism of apoptosis, which suggest that ART is likely to be a potential drug in the treatment of leukemia/lymphoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Artemisinins / pharmacology. Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067115.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Artemisinins; 04079A1RDZ / Cytarabine; 60W3249T9M / artesunate
  •  go-up   go-down


20. Onciu M: Acute lymphoblastic leukemia. Hematol Oncol Clin North Am; 2009 Aug;23(4):655-74
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia and lymphoblastic lymphoma constitute a family of genetically heterogeneous lymphoid neoplasms derived from B- and T-lymphoid progenitors.
  • [MeSH-major] Immunophenotyping / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Diagnosis, Differential. Flow Cytometry. Gene Rearrangement. Humans. Immunoglobulins / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577163.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 105
  •  go-up   go-down


21. Abdelouahed K, Laghmari M, Tachfouti S, Cherkaoui W, Khorassani M, M'Seffer FA, Mohcine Z: [T-cell acute lymphoblastic leukemia /orbital lymphoblastic lymphoma in children]. J Fr Ophtalmol; 2005 Feb;28(2):197-200
Genetic Alliance. consumer health - Orbital lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [T-cell acute lymphoblastic leukemia /orbital lymphoblastic lymphoma in children].
  • [Transliterated title] Leucémie aiguë lymphoblastique T/Lymphome lymphoblastique orbitaire chez l'enfant.
  • RESULTS: Incisional biopsy of the mass revealed after of histopathologic and immuno-histochemical evaluation a T-cell lymphoblastic lymphoma.
  • Systemic examination and bone marrow aspirate show a acute lymphoblastic leukemia.
  • CONCLUSION: Primary T-cell lymphoblastic lymphoma of the orbit is a rare entity in any age group, but it is very rare in children.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell. Neoplasms, Multiple Primary. Orbital Neoplasms. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15851954.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol; 2010 Mar;34(3):327-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
  • B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL).
  • Six patients had a history of grade 1 to 2 follicular lymphoma; review of the prior biopsy specimens in 2 of 5 cases revealed blastoid morphology.
  • Twelve DHL cases (60%) were classified as B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL, 7 cases (35%) as DLBCL, not otherwise specified, and 1 case as B-LBL.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Genes, Immunoglobulin Heavy Chain. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-myc / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):525-34 [10757399.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1960-6 [11069032.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):52-4 [11120335.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):610-3 [12708908.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):474-9 [15239399.001]
  • [Cites] Blood. 1983 Nov;62(5):1142-6 [6605167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Am J Clin Pathol. 1986 May;85(5):636-40 [3486584.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] N Engl J Med. 1988 May 26;318(21):1373-8 [3285208.001]
  • [Cites] Oncogene. 1988 May;2(5):431-5 [3131717.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1454-9 [2509518.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Oncogene. 1991 Jan;6(1):145-8 [1992441.001]
  • [Cites] Leukemia. 1991 Jan;5(1):83-7 [1999960.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Ann Hematol. 1991 Nov;63(5):282-7 [1958753.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):101-4 [1554791.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leukemia. 1994 Apr;8(4):560-3 [8152251.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):87-94 [8019967.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):414-23 [15852472.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1490-6 [16224216.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2313-23 [16193090.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):52-6 [17074591.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1061-4 [17182663.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):157-66 [18089500.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1593-607 [18753947.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):716-25 [19120369.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 20118770.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA076404; United States / NIGMS NIH HHS / GM / T32 GM074897; United States / NIGMS NIH HHS / GM / T32 GM074897-07
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS305320; NLM/ PMC3152212
  •  go-up   go-down


23. Lamb LS Jr, Neuberg R, Welsh J, Best R, Stetler-Stevenson M, Sorrell A: T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia. Cytometry B Clin Cytom; 2005 May;65(1):37-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia.
  • This case represents an example of an unusual T-cell lymphoblastic leukemia/lymphoma syndrome associated with eosinophilia and myeloid malignancy in a young boy.
  • This case is one of only five reported "leukemic" variants of the disease and demonstrates the importance of considering this poor prognostic diagnosis in pediatric acute lymphoblastic leukemia.
  • This case also illustrates the importance of an interactive multidisciplinary approach to the laboratory evaluation of a leukemia patient.
  • [MeSH-major] Eosinophilia / complications. Leukemia, Myeloid, Acute / complications. Leukemia-Lymphoma, Adult T-Cell / complications. Lymphoma / complications


24. O'Brien MM, Lee-Kim Y, George TI, McClain KL, Twist CJ, Jeng M: Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer; 2008 Feb;50(2):381-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis.
  • HLH with B-cell malignancies is less common and HLH has rarely been described in association with precursor B-cell acute lymphoblastic leukemia (B-ALL).
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


25. Jabbour EJ, Faderl S, Kantarjian HM: Adult acute lymphoblastic leukemia. Mayo Clin Proc; 2005 Nov;80(11):1517-27
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia.
  • Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16295033.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


26. Ansari M, St-Onge G, Krajinovic M: [Pharmacogenomics of acute lymphoblastic leukemia]. Med Sci (Paris); 2007 Nov;23(11):961-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacogenomics of acute lymphoblastic leukemia].
  • [Transliterated title] Pharmacogénétique de la leucémie lymphoblastique aiguë
  • Pharmacogenomics of acute lymphoblastic leukemia (ALL) evolved rapidly in the past few years.
  • Leukemia is the most common cancer affecting children, with ALL comprising 80 % of all leukemia cases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021708.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; E7WED276I5 / 6-Mercaptopurine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. DeAngelo DJ: Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am; 2009 Oct;23(5):1121-35, vii-viii
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
  • Nelarabine has significant activity in patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL).
  • [MeSH-major] Arabinonucleosides / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825456.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  • [Number-of-references] 34
  •  go-up   go-down


28. Greve J, Bas M, Schipper J, Hoffmann TK: [Primary cutane manifestation of a precursor-B-lymphoblastic lymphoma in the external ear]. Laryngorhinootologie; 2008 Oct;87(10):728-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cutane manifestation of a precursor-B-lymphoblastic lymphoma in the external ear].
  • A Non-Hodgkin Lymphoma (NHL) represents nearly three percent of all malignant tumors.
  • We report on an extranodal B-cell-lymphoma of the ear in a young woman.
  • In spite of the considerable extent of the lymphoma there was no systemic manifestation and a total remission was induced by chemotherapy before adjuvant radiation.
  • [MeSH-major] Ear Neoplasms / diagnosis. Ear, External. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633860.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Kager L, Evans WE: Pharmacogenomics of acute lymphoblastic leukemia. Curr Opin Hematol; 2006 Jul;13(4):260-5
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenomics of acute lymphoblastic leukemia.
  • PURPOSE OF REVIEW: The cure rate in children with acute lymphoblastic leukemia now exceeds almost 80% in most treatment protocols in industrialized countries.
  • Pharmacogenomics, which studies the role of inheritance in individual variation in drug disposition and response, could be a useful tool to further improve outcome in this heterogeneous disease by individualization of therapy based on information gained from the genetic 'make-up' of normal host cells and lymphoblastic leukemia cells.
  • Thus there is great promise for advancing event-free survival in childhood leukemia in the future.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pharmacogenetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755223.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 49
  •  go-up   go-down


30. Goldstone AH: Transplantations in adult acute lymphoblastic leukemia--grounds for optimism? Clin Lymphoma Myeloma; 2009;9 Suppl 3:S211-3
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantations in adult acute lymphoblastic leukemia--grounds for optimism?
  • The large MRC/ECOG Adult Acute Lymphoblastic Leukemia Study establishes the value of sibling donor allogeneic transplantation in patients with standard risk, demonstrating superior outcome to conventional chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Medical Oncology / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778843.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 6
  •  go-up   go-down


31. Cohen MH, Johnson JR, Massie T, Sridhara R, McGuinn WD Jr, Abraham S, Booth BP, Goheer MA, Morse D, Chen XH, Chidambaram N, Kenna L, Gobburu JV, Justice R, Pazdur R: Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res; 2006 Sep 15;12(18):5329-35
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
  • PURPOSE: To describe the clinical studies, chemistry manufacturing and controls, and clinical pharmacology and toxicology that led to Food and Drug Administration approval of nelarabine (Arranon) for the treatment of T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.
  • CONCLUSIONS: On October 28, 2005, the Food and Drug Administration granted accelerated approval for nelarabine for treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma after at least two prior regimens.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Drug Approval. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. United States Food and Drug Administration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000665.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  •  go-up   go-down


32. Razzouk BI, Rose SR, Hongeng S, Wallace D, Smeltzer MP, Zacher M, Pui CH, Hudson MM: Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol; 2007 Apr 1;25(10):1183-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma.
  • PURPOSE: We evaluated the long-term effects of treatment on the body mass index (BMI) of children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma who received one of three CNS-directed therapies: intrathecal methotrexate with intravenous high-dose methotrexate (1 g/m2), intrathecal methotrexate with 18 Gy cranial radiation, or intrathecal methotrexate with 24 Gy cranial radiation.
  • PATIENTS AND METHODS: Between 1979 and 1984, 456 children with newly diagnosed ALL and lymphoma were enrolled onto a single protocol at St Jude Children's Research Hospital (Memphis, TN).
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Cranial Irradiation / adverse effects. Methotrexate / adverse effects. Obesity / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


33. Mullighan CG: T-lineage lymphoblastic lymphoma and leukemia-a MASSive problem. Cancer Cell; 2010 Oct 19;18(4):297-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-lineage lymphoblastic lymphoma and leukemia-a MASSive problem.
  • T cell precursor malignancies may present as T-lymphoblastic lymphoma (T-LBL) with marked enlargement of lymph nodes or acute T-lymphoblastic leukemia (T-ALL) with little lymph node enlargement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [CommentOn] Cancer Cell. 2010 Oct 19;18(4):353-66 [20951945.001]
  • (PMID = 20951938.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, Deryckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, Johnson GL, Graham DK: Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene; 2006 Oct 5;25(45):6092-100
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.
  • Mer is not normally expressed in thymocytes or lymphocytes; however, ectopic Mer RNA transcript and protein expression is found in a subset of acute lymphoblastic leukemia cell lines and patient samples, suggesting a role in leukemogenesis.
  • Histopathological analysis and flow cytometry were consistent with T-cell lymphoblastic leukemia/lymphoma.
  • These data suggest that Mer plays a cooperative role in leukemogenesis and may be an effective target for biologically based leukemia/lymphoma therapy.


35. Kato I, Manabe A, Aoyama C, Kamiya T, Morimoto T, Matsufuji H, Suzuki K, Kitagawa Y, Hori T, Tsurusawa M, Kiyokawa N, Junichiro F, Hosoya R: Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Feb;48(2):230-2
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia.
  • Non-Hodgkin lymphoma (NHL) is a very rare complication of acute lymphoblastic leukemia (ALL).
  • While he was receiving maintenance treatment 2 years and 9 months after the diagnosis of ALL, diffuse large B cell lymphoma (DLBL) was diagnosed from a biopsy of an abdominal mass.
  • [MeSH-major] Lymphoma, B-Cell / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


36. Radhakrishnan N, Sachdeva A, Oberoi J, Yadav SP: Conidiobolomycosis in relapsed acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Dec 15;53(7):1321-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conidiobolomycosis in relapsed acute lymphoblastic leukemia.
  • Here we report the isolation of Conidiobolus coronatus, a rarely reported zygomycetes infection in a patient suffering from acute lymphoblastic leukemia.
  • [MeSH-major] Conidiobolus / isolation & purification. Maxillary Sinusitis / etiology. Orbital Cellulitis / etiology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / complications. Zygomycosis / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19731329.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 7XU7A7DROE / Amphotericin B; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


37. Mantadakis E, Danilatou V, Stiakaki E, Paterakis G, Papadhimitriou S, Kalmanti M: T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia. Pediatr Blood Cancer; 2007 Mar;48(3):354-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia.
  • We present the unusual case of a 16-year-old girl with T-cell acute lymphoblastic leukemia (ALL) with an early thymocyte immunophenotype without myeloid markers, who after 13 months of complete hematological remission relapsed as acute myelogenous leukemia (AML) with minimal differentiation and died of her disease.
  • [MeSH-major] Antigens, Differentiation, T-Lymphocyte / analysis. Antigens, Neoplasm / analysis. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Neoplastic Stem Cells / pathology. T-Lymphocyte Subsets / pathology
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Acute Disease. Adolescent. Antigens, CD7 / analysis. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Bone Marrow / pathology. Cell Differentiation. Cell Lineage. Core Binding Factor Alpha 2 Subunit / genetics. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Etoposide / adverse effects. Fatal Outcome. Female. Gene Dosage. Histone-Lysine N-Methyltransferase. Humans. Immunophenotyping. Karyotyping. Methotrexate / administration & dosage. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasms, Second Primary / diagnosis. Proto-Oncogenes. Recurrence. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16206214.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD7; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / Core Binding Factor Alpha 2 Subunit; 0 / MLL protein, human; 0 / RUNX1 protein, human; 04079A1RDZ / Cytarabine; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


38. Wang RC, Jan YJ, Wen MC, Wang J, Hsieh PP: Primary appendiceal precursor B lymphoblastic lymphoma with peculiar morphology mimicking diffuse large B cell lymphoma. Pathol Int; 2010 Oct;60(10):690-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary appendiceal precursor B lymphoblastic lymphoma with peculiar morphology mimicking diffuse large B cell lymphoma.
  • Precursor B lymphoblastic neoplasm usually presented as childhood leukemia.
  • Most precursor lymphoblastic lymphoma are T-cell lineage and precursor B lymphoblastic lymphoma constitutes only about 10% of cases according to the WHO Classification of Tumours of Haematologic and Lymphoid Tissues.
  • The most frequent sites of involvement in precursor B lymphoblastic lymphoma are the skin, soft tissue, bone and lymph nodes.
  • We present an unusual case of primary appendiceal precursor B lymphoblastic lymphoma in an 11-year-old boy with peculiar histological morphology mimicking diffuse large B cell lymphoma.
  • The response to conventional treatment regimen for lymphoblastic lymphoma was not good, with early relapse within three months.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 20846268.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


39. Cheok MH, Pottier N, Kager L, Evans WE: Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):39-51
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetics in acute lymphoblastic leukemia.
  • Progress in the treatment of acute lymphoblastic leukemia (ALL) in children has been remarkable, from a disease being lethal four decades ago to current cure rates exceeding 80%.
  • However, despite these high cure rates, the annual number of children whose leukemia relapses after their initial therapy remains greater than that of new cases of most types of childhood cancers.
  • These studies illustrate the promise of pharmacogenomics to further advance the treatment of human cancers, with childhood leukemia serving as a paradigm.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):847-56 [10866211.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):857-65 [10866212.001]
  • [Cites] Nat Genet. 2000 Oct;26(2):135-7 [11017062.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Clin Chem. 2001 Feb;47(2):164-72 [11159763.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):928-33 [11237013.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2293-301 [11304783.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2948-58 [11387368.001]
  • [Cites] Genome Res. 2001 Jul;11(7):1262-8 [11435409.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7225-32 [11585759.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1669-70 [11721042.001]
  • [Cites] Nat Rev Genet. 2001 Dec;2(12):930-42 [11733746.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:113-33 [11807167.001]
  • [Cites] Nat Rev Genet. 2002 May;3(5):391-7 [11988764.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 [12084458.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Curr Opin Pharmacol. 2002 Dec;2(6):723-9 [12482737.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):529-37 [12571261.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):538-49 [12571262.001]
  • [Cites] Haematologica. 2003 Mar;88(3):353-4 [12651279.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):518-21 [12652300.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Nat Med. 2003 May;9(5):510-1 [12724758.001]
  • [Cites] Science. 2003 Jul 4;301(5629):102-5 [12843395.001]
  • [Cites] Pharmacogenetics. 2003 Sep;13(9):577-80 [12972956.001]
  • [Cites] Nat Biotechnol. 2003 Oct;21(10):1233-7 [12960966.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Nat Rev Genet. 2003 Dec;4(12):1001-8 [14631360.001]
  • [Cites] Cell Death Differ. 2004 Feb;11(2):165-74 [14576768.001]
  • [Cites] Pharmacogenomics J. 2004;4(1):66-72 [14647408.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):257-63 [14770183.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):214-5 [14988717.001]
  • [Cites] Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R57-64 [14764619.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3347-58 [15060156.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Cell Death Differ. 2004 Jul;11 Suppl 1:S45-55 [15243581.001]
  • [Cites] Pharmacogenetics. 2004 Aug;14(8):557-67 [15284538.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3930-6 [15459215.001]
  • [Cites] J Biol Chem. 1980 Jun 25;255(12):5776-88 [6892914.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] J Clin Invest. 1985 Sep;76(3):907-12 [2413074.001]
  • [Cites] N Engl J Med. 1986 Feb 20;314(8):471-7 [3456079.001]
  • [Cites] J Steroid Biochem. 1987;27(1-3):201-8 [3501039.001]
  • [Cites] Blood. 1990 Jul 1;76(1):44-9 [1694703.001]
  • [Cites] Lancet. 1990 Jul 28;336(8709):225-9 [1973780.001]
  • [Cites] J Pediatr. 1991 Dec;119(6):985-9 [1960624.001]
  • [Cites] Annu Rev Genet. 1991;25:281-314 [1687498.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):949-53 [7862671.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):377-83 [15765094.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1437-42 [12145682.001]
  • [Cites] Steroids. 2005 May-Jun;70(5-7):407-17 [15862824.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):99-108 [11905809.001]
  • [Cites] Pharmacogenetics. 2002 Apr;12(3):181-2 [11927832.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1033-4 [11937185.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):895-905 [9001244.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]
  • [Cites] Blood. 1999 May 1;93(9):2817-23 [10216075.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2532-5 [10363967.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1209-17 [10438708.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1072-9 [15718463.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2482-7 [15781665.001]
  • [Cites] JAMA. 2005 Mar 23;293(12):1485-9 [15784872.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3053-8 [15833833.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):277-85 [15864128.001]
  • [Cites] Blood. 2005 Jul 15;106(2):717-20 [15797993.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):878-82 [16041371.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1299-320 [16255080.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Annu Rev Med. 2006;57:119-37 [16409140.001]
  • [Cites] Leukemia. 2006 Feb;20(2):239-46 [16341039.001]
  • [Cites] Leukemia. 2006 Jan;20(1):9-17 [16281070.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1113-6 [16870553.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1929-35 [17008526.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Nat Biotechnol. 2006 Sep;24(9):1151-61 [16964229.001]
  • [Cites] Clin Pharmacol Ther. 2006 Nov;80(5):468-76 [17112803.001]
  • [Cites] Science. 2007 Jan 26;315(5811):525-8 [17185560.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] Science. 2007 Apr 27;316(5824):550-1 [17463274.001]
  • [Cites] Blood. 2007 May 15;109(10):4151-7 [17264302.001]
  • [Cites] Nature. 2007 May 10;447(7141):161-5 [17495918.001]
  • [Cites] Nat Genet. 2007 Jul;39(7 Suppl):S7-15 [17597783.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13513-8 [17686970.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1429-38 [17495134.001]
  • [Cites] Hum Mol Genet. 2007 Oct 1;16(19):2261-71 [17616514.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2128-36 [17673902.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1561-4 [18024406.001]
  • [Cites] Methods. 2008 Jan;44(1):22-30 [18158129.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2984-90 [18182569.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3692-700 [18096764.001]
  • [Cites] Blood. 2008 May 1;111(9):4496-9 [18285546.001]
  • [Cites] PLoS Med. 2008 Apr 15;5(4):e83 [18416598.001]
  • [Cites] PLoS One. 2008;3(5):e2144 [18478092.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jun;18(6):507-14 [18496130.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 17;100(24):1792-803 [19066270.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1049-57 [17380207.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Int J Hematol. 1999 Dec;70(4):268-77 [10643153.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2004-13 [10688647.001]
  • (PMID = 19100367.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA036401-25; United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NCI NIH HHS / CA / CA21765; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA036401-25; United States / NCI NIH HHS / CA / R01 CA78224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 120
  • [Other-IDs] NLM/ NIHMS89418; NLM/ PMC2665795
  •  go-up   go-down


40. Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, Müschen M: BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene; 2006 Feb 16;25(7):1118-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
  • Pre-B lymphoblastic leukemia cells carrying a BCR-ABL1 gene rearrangement exhibit an undifferentiated phenotype.
  • Comparing the genome-wide gene expression profiles of normal B-cell subsets and BCR-ABL1+ pre-B lymphoblastic leukemia cells by SAGE, the leukemia cells show loss of B lymphoid identity and aberrant expression of myeloid lineage-specific molecules.
  • Consistent with this, BCR-ABL1+ pre-B lymphoblastic leukemia cells exhibit defective expression of IKAROS, a transcription factor needed for early lymphoid lineage commitment.
  • As shown by inducible expression of BCR-ABL1 in human and murine B-cell precursor cell lines, BCR-ABL1 induces the expression of a dominant-negative IKAROS splice variant, termed IK6.
  • Comparing matched leukemia sample pairs from patients before and during therapy with the BCR-ABL1 kinase inhibitor STI571 (Imatinib), inhibition of BCR-ABL1 partially corrected aberrant expression of IK6 and lineage infidelity of the leukemia cells.
  • Upon inhibition of IK6, BCR-ABL1+ leukemia cells partially restored B lymphoid lineage commitment.
  • Therefore, we propose that BCR-ABL1 induces aberrant splicing of IKAROS, which interferes with lineage identity and differentiation of pre-B lymphoblastic leukemia cells.
  • [MeSH-major] Alternative Splicing. Ikaros Transcription Factor / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Tyrosine Kinases / metabolism

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205638.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / IKZF1 protein, human; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 148971-36-2 / Ikaros Transcription Factor; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


41. Burkhardt B: Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases? Br J Haematol; 2010 Jun;149(5):653-68
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases?
  • There is ongoing discussion on whether paediatric acute T-cell lymphoblastic leukaemia (T-ALL) and paediatric lymphoblastic T-cell lymphoma (T-LBL) are two distinct entities or whether they represent two variant manifestations of one and the same disease and the distinction is arbitrary.
  • The current World Health Organization classification designates both malignancies as T lymphoblastic leukaemia/lymphoma.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961482.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 105
  •  go-up   go-down


42. Sweetenham JW: Treatment of lymphoblastic lymphoma in adults. Oncology (Williston Park); 2009 Nov 15;23(12):1015-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of lymphoblastic lymphoma in adults.
  • Lymphoblastic lymphoma is a rare disease in adults, primarily affecting patients in their late teens and early 20s.
  • Optimal treatment strategies have been slow to emerge because of the rarity of this disease and the variable distinction in the clinical literature between this condition and acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2009 Nov 15;23(12):1020, 1026 [20017284.001]
  • (PMID = 20017283.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


43. Forester CM, Braunreiter CL, Yaish H, Hedlund GL, Afify Z: Tumefactive intracranial presentation of precursor B-cell acute lymphoblastic leukemia. Pediatr Radiol; 2009 Nov;39(11):1230-3
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumefactive intracranial presentation of precursor B-cell acute lymphoblastic leukemia.
  • In children, leukemia is the most common malignancy, and approximately 75% of leukemias are acute lymphoblastic leukemia (ALL).
  • Central nervous system leukemia is found at diagnosis in fewer than 5% of children with ALL.
  • Leukemic intracranial masses have been described with acute myeloid leukemia, but ALL presenting as a mass lesion is rare.
  • We describe a unique case of an intracranial confirmed precursor B cell (pre-B) ALL mass in a 13-year-old girl that was diagnosed by brain CT, MRI and cerebral angiography, and confirmed by biopsy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cerebral Angiography / methods. Magnetic Resonance Imaging / methods. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Spring;11(1):57-63 [2712245.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2082-90 [15341983.001]
  • [Cites] Pediatr Neurol. 2002 Nov;27(5):401-3 [12504211.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):48-55 [16844335.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):135-7 [18383153.001]
  • [Cites] Pediatr Clin North Am. 1988 Aug;35(4):789-814 [3047654.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Aug;17(7):1365-71 [8871726.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Sep;28(8):1462-5 [17846191.001]
  • (PMID = 19763560.001).
  • [ISSN] 1432-1998
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Onda K, Iijima K, Katagiri YU, Okita H, Saito M, Shimizu T, Kiyokawa N: Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma. Int J Hematol; 2010 Jun;91(5):808-19
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma.
  • We investigated BCP acute lymphoblastic leukemia (-ALL) cells for BAFF receptor (-R) expression and compared the effect of BAFF on BCP-ALL cells and Burkitt lymphoma (BL) cells.
  • [MeSH-major] B-Cell Activating Factor / immunology. B-Cell Activation Factor Receptor / genetics. Burkitt Lymphoma / immunology. Gene Expression Regulation, Leukemic. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cells, B-Lymphoid / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2003 Jul 15;171(2):547-51 [12847217.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1747-56 [10359578.001]
  • [Cites] Blood. 2004 Jan 15;103(2):689-94 [14512299.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):137-43 [10880535.001]
  • [Cites] Immunology. 2006 Jul;118(3):281-92 [16827889.001]
  • [Cites] J Leukoc Biol. 1999 May;65(5):680-3 [10331498.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):15978-81 [10347144.001]
  • [Cites] Eur J Haematol. 2008 Sep;81(3):177-84 [18510703.001]
  • [Cites] Nature. 2000 Apr 27;404(6781):995-9 [10801128.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3268-79 [14978135.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35478-85 [10956646.001]
  • [Cites] J Immunol. 2001 May 1;166(9):5567-77 [11313396.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):327-36 [17433868.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2108-11 [11509692.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):18656-65 [9228035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9156-61 [10908663.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5820-3 [12794106.001]
  • [Cites] Immunity. 2002 Oct;17(4):515-24 [12387744.001]
  • [Cites] J Immunol. 2003 Jan 1;170(1):252-60 [12496407.001]
  • [Cites] Histopathology. 2009 Jan;54(2):221-32 [19207947.001]
  • [Cites] Curr Biol. 2000 Jun 29;10(13):785-8 [10898980.001]
  • [Cites] Immunology. 2008 Dec;125(4):570-90 [18540961.001]
  • [Cites] Blood. 2007 Jan 15;109(2):729-39 [16960154.001]
  • [Cites] Science. 1999 Jul 9;285(5425):260-3 [10398604.001]
  • [Cites] Exp Hematol. 2006 Apr;34(4):508-18 [16569597.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1697-710 [10587360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3370-5 [10716715.001]
  • [Cites] Curr Opin Immunol. 2005 Jun;17(3):282-9 [15886118.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2111-4 [11509691.001]
  • [Cites] Clin Exp Immunol. 1990 Mar;79(3):322-7 [2138527.001]
  • [Cites] Exp Hematol. 2002 Oct;30(10):1115-23 [12384141.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2247-53 [15251985.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):129-35 [10880534.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1164-74 [12764385.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3148-57 [15070697.001]
  • [Cites] Int Immunol. 1995 Jul;7(7):1093-106 [8527407.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):3015-23 [15728515.001]
  • [Cites] Immunity. 2001 Aug;15(2):289-302 [11520463.001]
  • [Cites] J Immunol. 1995 Apr 1;154(7):3096-104 [7534787.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1644-52 [9473230.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1113-9 [16226112.001]
  • (PMID = 20428981.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / B-Cell Activating Factor; 0 / B-Cell Activation Factor Receptor
  •  go-up   go-down


45. Ju X, Li D, Shi Q, Hou H, Sun N, Shen B: Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2009 Jan;26(1):1-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia.
  • The analysis of differential microRNA expression profiles may be a powerful tool to allow us insight on the mechanisms of childhood B-cell precursor acute lymphoblastic leukemia (pre-B-ALL).
  • [MeSH-major] Gene Expression Regulation, Neoplastic. MicroRNAs / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Child, Preschool. Computational Biology. Gene Expression Profiling. Hematopoiesis / genetics. Humans. Infant. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19206004.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN222 microRNA, human; 0 / MIRN373 microRNA, human; 0 / MIRN451 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


46. Ahmed D, Ahmed TA, Ahmed S, Tipu HN, Wiqar MA: CD5-positive acute lymphoblastic leukemia. J Coll Physicians Surg Pak; 2008 May;18(5):310-1
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD5-positive acute lymphoblastic leukemia.
  • CD5-positive B-ALL is a rare variant of Acute Lymphoblastic Leukemia (ALL).
  • This fourth case report describes a young lady who was diagnosed as ALL (L-2) on bone marrow examination and was found to be CD5 positive B-cell acute lymphoblastic leukemia on immunophenotyping.
  • [MeSH-major] Antigens, CD5 / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541090.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


47. Belgaumi AF, Al-Kofide A, Sabbah R, Shalaby L: Precursor B-cell lymphoblastic lymphoma (PBLL) in children: pattern of presentation and outcome. J Egypt Natl Canc Inst; 2005 Mar;17(1):15-9
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic lymphoma (PBLL) in children: pattern of presentation and outcome.
  • PURPOSE AND BACKGROUND: Precursor B-cell lymphoblastic lymphoma (PBLL) is a rare subtype of NHL seen primarily in children or young adults.
  • RESULTS: Twenty one patients were treated for lymphoblastic lymphoma, of which six had a precursor Bcell phenotype.
  • [MeSH-major] B-Lymphocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353078.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


48. Hoelzer D, Gökbuget N: T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma; 2009;9 Suppl 3:S214-21
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
  • T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are considered the same disease, differing by the extent of bone marrow infiltration.
  • Treatment approaches in T-LBL changed from conventional non-Hodgkin lymphoma (NHL) protocols to intensive NHL protocols but recently to ALL-designed protocols.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778844.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


49. Landman-Parker J, Pagès P, Petit A, Fasola S, Leverger G: [New insights into acute lymphoblastic leukemia]. Bull Acad Natl Med; 2009 Oct;193(7):1501-7
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New insights into acute lymphoblastic leukemia].
  • [Transliterated title] Que savons-nous de la cellule leucémique?
  • Acute lymphoblastic leukemia is a malignant disorder of lymphoid progenitor cells.
  • Advances in our understanding of lymphoblastic leukemia have mainly come from new molecular technologies and genomics.
  • [MeSH-major] Lymphocyte Subsets / pathology. Neoplastic Stem Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669631.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CCR7 protein, human; 0 / Chemokines; 0 / Receptors, CCR7
  • [Number-of-references] 32
  •  go-up   go-down


50. Sadruddin S, Medeiros LJ, DeMonte F: Primary T-cell lymphoblastic lymphoma of the cavernous sinus. J Neurosurg Pediatr; 2010 Jan;5(1):94-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary T-cell lymphoblastic lymphoma of the cavernous sinus.
  • The rare occurrence of T-cell lymphoblastic lymphoma as a primary tumor in the cavernous sinus is described.
  • Rapid progression of symptoms led to open biopsy, and a diagnosis of T-cell lymphoblastic lymphoma was made.
  • [MeSH-major] Cavernous Sinus. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043743.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


51. Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C, Zimmermann M, Strauch K, Ludwig WD, Schrappe M, Reiter A: Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma; 2008 Mar;49(3):451-61
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact.
  • This study analyzed loss of heterozygosity (LOH) at chromosome 6q and compared the LOH findings in pediatric precursor T lymphoblastic lymphoma (T-LBL) with the LOH findings in precursor-T lymphoblastic leukemia (T-ALL).
  • [MeSH-major] Chromosomes, Human, Pair 6. Loss of Heterozygosity. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297521.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


52. Jiang H, Gu LJ, Xue HL, Tang JY, Chen J, Pan C, Chen J, Xu C, Dong L, Zhou M: [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun;10(3):290-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
  • OBJECTIVE: To study the prognostic factors for events-free survival (EFS) in children with acute non-mature B-lymphoblastic leukemia.
  • METHODS: One hundred and sixty-one children with newly diagnosed acute non-mature B-lymphoblastic leukemia received the ALL-XH-99 protocol treatment.
  • CONCLUSIONS: WBC >or=50 x 10(9)/L, Cmu positive, BCR/ABL or MLL/AF4 positive and MRD positive have important prognostic values in childhood acute non-mature B-lymphoblastic leukemia.
  • [MeSH-major] Burkitt Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Genes, abl. Humans. Infant. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasm, Residual. Oncogene Proteins, Fusion / genetics. Prognosis. Regression Analysis


53. Steiner M, Attarbaschi A, Dworzak M, Strobl H, Pickl W, Kornmüller R, Haas O, Gadner H, Mann G, Austrian Berlin-Frankfurt-Münster Study Group: Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. J Pediatr Hematol Oncol; 2010 Jan;32(1):e4-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia.
  • Rarely, cytochemical MPO reaction may be positive in >or=3% of blasts with clear lymphoblastic morphology.
  • We present 5 patients with cytochemically MPO-positive acute leukemia classified as lymphoblastic by cytomorphology and lymphoblastic (n=3) or biphenotypic (n=2) by immunophenotyping, who entered first-line treatment for lymphoblastic leukemia.
  • The former 3 are in first remission and both with biphenotypic leukemia relapsed with acute myeloid leukemia.
  • The study primarily shows that cytochemical MPO expression in childhood acute leukemia revealing typical lymphoblastic morphology and phenotype does rarely exist.
  • Although a small number of patients studied, cytochemical MPO expression in acute leukemia does not seem to require myeloid leukemia treatment in case of otherwise lymphoblastic cytomorphology and phenotype.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Peroxidase / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935430.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


54. Breakey VR, Abdelhaleem M, Weitzman S, Abla O: Hemophagocytic lymphohistiocytosis onset during induction therapy for precursor B-cell acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Dec;30(12):956-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemophagocytic lymphohistiocytosis onset during induction therapy for precursor B-cell acute lymphoblastic leukemia.
  • We report the clinical course of a child with precursor B-cell acute lymphoblastic leukemia who developed fever, hepatosplenomegaly, and refractory thrombocytopenia after initiation of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphohistiocytosis, Hemophagocytic / chemically induced. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Hemophagocytic Lymphohistiocytosis (HLH).
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131791.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


55. Matsouka C, Marinopoulos S, Barbaroussi D, Antsaklis A: Acute lymphoblastic leukemia during gestation. Med Oncol; 2008;25(2):190-3
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia during gestation.
  • The management of the common acute lymphoblastic leukemia in pregnancy has been controversial, but currently aggressive chemotherapy is the practice trend worldwide.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pregnancy Complications, Neoplastic / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol Clin North Am. 1998 Jun;25(2):323-9 [9629573.001]
  • [Cites] Obstet Gynecol. 2001 May;97(5 Pt 2):809-12 [11336761.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):110-7 [15912518.001]
  • [Cites] Can Fam Physician. 2001 Jan;47:41-2 [11212430.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):904-8 [14675333.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1556-64 [9716583.001]
  • [Cites] Obstet Gynecol Clin North Am. 1998 Jun;25(2):273-85 [9629570.001]
  • [Cites] Klin Padiatr. 2005 Nov-Dec;217(6):310-20 [16307416.001]
  • [Cites] Clin Lab Haematol. 2006 Jun;28(3):170-6 [16706933.001]
  • [Cites] Lancet Oncol. 2004 May;5(5):283-91 [15120665.001]
  • [Cites] Obstet Gynecol Clin North Am. 1998 Jun;25(2):365-83 [9629577.001]
  • [Cites] Clin Lymphoma. 2001 Dec;2(3):173-7 [11779294.001]
  • [Cites] Leuk Res. 2003 May;27(5):381-5 [12620288.001]
  • (PMID = 18040902.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Peterson MR, Noskoviak KJ, Newbury R: CD5-positive B-cell acute lymphoblastic leukemia. Pediatr Dev Pathol; 2007 Jan-Feb;10(1):41-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD5-positive B-cell acute lymphoblastic leukemia.
  • CD5-positive B-cell acute lymphoblastic leukemia (ALL) is an exceedingly rare entity, with only a single case report in the literature.
  • [MeSH-major] Antigens, CD5 / metabolism. Biomarkers, Tumor / analysis. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology
  • [MeSH-minor] Adolescent. Antigens, CD / metabolism. Biopsy. Bone Marrow / pathology. Bone Marrow / surgery. Diagnosis, Differential. Diagnostic Errors. Female. Flow Cytometry. Humans. Immunohistochemistry. Leukemia / pathology. Lymphoma / pathology. Male. Prognosis. Sarcoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378623.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD5; 0 / Biomarkers, Tumor
  •  go-up   go-down


57. Rytting M: Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther; 2010 May;10(5):833-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peg-asparaginase for acute lymphoblastic leukemia.
  • IMPORTANCE OF THE FIELD: Asparaginase is a prominent component of pediatric and adolescent treatment for acute lymphoblastic leukemia.
  • AREAS COVERED BY THIS REVIEW: The search terms used were asparaginase, leukemia, pegylated, oncaspar, adolescent and young adult.
  • WHAT THE READER WILL GAIN: The reader will gain knowledge of the tolerability and efficacy of pegylated asparaginase when treating acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Asparaginase / therapeutic use. Polyethylene Glycols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20345338.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; EC 3.5.1.1 / Asparaginase
  • [Number-of-references] 33
  •  go-up   go-down


58. Morrissette JJ, Halligan GE, Punnett HH, McKenzie AS, Guerrero F, de Chadarévian JP: Down syndrome with low hypodiploidy in precursor B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2006 Aug;169(1):58-61
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down syndrome with low hypodiploidy in precursor B-cell acute lymphoblastic leukemia.
  • We describe the rare finding of a 33-month-old child neonatally diagnosed with Down syndrome, who presented with pre-B acute lymphoblastic leukemia (ALL) with a pretreatment bone marrow karyotype in which a low hypodiploid cell line (38 chromosomes) was identified in 17/19 cells studied.
  • [MeSH-major] Burkitt Lymphoma / genetics. Diploidy. Down Syndrome / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875938.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. de Souza Thiago L, da Costa ES, Lopes DV, Borojevic R: Racemic Etodolac is cytotoxic and cytostatic for B-cell precursor acute lymphoblastic leukemia cells. Biomed Pharmacother; 2009 Aug;63(7):548-51
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racemic Etodolac is cytotoxic and cytostatic for B-cell precursor acute lymphoblastic leukemia cells.
  • Several epidemiological studies have provided evidence that administration of nonsteroidal anti-inflammatory drugs (NSAIDs) could have a prophylactic effect against some cancers such as sporadic colorectal cancer and leukemia.
  • We evaluated the effect of racemic Etodolac on proliferation and cell survival in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells.
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Humans. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Stereoisomerism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18993025.001).
  • [ISSN] 1950-6007
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antimetabolites, Antineoplastic; 0 / Cytostatic Agents; 2M36281008 / Etodolac
  •  go-up   go-down


60. Mansour MR: Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma. Expert Rev Hematol; 2009 Apr;2(2):133-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma.
  • Mutations of the Ras family are one of the most common somatic events found in all human cancers, although they are relatively rare in T-cell acute lymphoblastic leukemia (T-ALL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2008 Oct 15;112(8):3373-82 [18663146.001]
  • (PMID = 21083447.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Liu Y: [Prognosis prediction for childhood acute lymphoblastic leukemia--review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb;15(1):202-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis prediction for childhood acute lymphoblastic leukemia--review].
  • Contemporary risk-directed therapy has advanced the cure rate for childhood acute lymphoblastic leukemia to near 80%.
  • The risk factors and systems of assessment in prognosis prediction for childhood acute lymphoblastic leukemia were summarised in this review.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490555.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 22
  •  go-up   go-down


62. Matano S, Terahata S, Nakamura S, Kobayashi K, Sugimoto T: CD56-positive acute lymphoblastic leukemia. Acta Haematol; 2005;114(3):160-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56-positive acute lymphoblastic leukemia.
  • We report a patient with lung cancer who developed CD56-positive acute lymphoblastic leukemia.
  • Systemic examination did not detect any tumors other than pulmonary adenocarcinoma, and the patient was diagnosed as having acute natural killer (NK) cell leukemia.
  • We considered that the diagnosis was blastic NK cell lymphoma/leukemia subtype.
  • However, it actually was myeloid/NK cell precursor leukemia subtype that weakly expressed CD13.
  • [MeSH-major] Antigens, CD56 / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 S. Karger AG, Basel
  • (PMID = 16227680.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


63. Raetz EA, Perkins SL, Bhojwani D, Smock K, Philip M, Carroll WL, Min DJ: Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer; 2006 Aug;47(2):130-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
  • BACKGROUND: T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) and are often thought to represent a spectrum of a single disease.
  • [MeSH-major] Gene Expression Profiling. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358311.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA88361
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


64. Correa-González LC, Mandeville PB, Manrique-Dueñas J, Alejo-González F, Salazar-Martínez A, de Pérez-Ramírez OJ, Hernández-Sierra JF: [Prognostic value of pre-B immunophenotype in early treatment response among acute pediatric lymphoblast leukemia patients]. Gac Med Mex; 2005 Nov-Dec;141(6):477-82
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic value of pre-B immunophenotype in early treatment response among acute pediatric lymphoblast leukemia patients].
  • [Transliterated title] Valor pronóstico del inmunofenotipo en la respuesta temprana de la leucemia aguda linfoblástica pre-B en niños.
  • OBJECTIVE: To determine the prognostic value of preB immunophenotype and its variants on early treatment response among of acute pediatric lymphoblast leukemia.
  • PATIENTS AND METHODS: A case-control study nested in a cohort was carried out with male and female patients 15 years and younger with recently diagnosed pre-B lymphoblast leukemia.
  • CONCLUSIONS: We need to pay special emphasis on early treatment response in children with lymphoblast leukemia as our study did not corroborate the common finding that clinical factors and immune phenotype can be predictive factors.
  • [MeSH-major] Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381501.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


65. Fais F, Tenca C, Cimino G, Coletti V, Zanardi S, Bagnara D, Saverino D, Zarcone D, De Rossi G, Ciccone E, Grossi CE: CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia; 2005 Apr;19(4):551-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis.
  • Acute lymphoblastic leukemia (ALL) is the most frequent malignancy of childhood.
  • We investigated CD1d expression in 80 pediatric B-cell precursor (BCP) ALL cases defined according to immunophenotype, cytogenetic features and age at onset.
  • CD1d+ ALLs were significantly associated with infant leukemia, pro-B phenotype and mixed-lineage leukemia (MLL)/AF4 gene rearrangement.
  • [MeSH-major] Antigens, CD1 / metabolism. Hematopoietic Stem Cells / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744356.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / Antigens, CD1d; 0 / Biomarkers, Tumor; 0 / CD1D protein, human; 0 / Galactosylceramides; 0 / alpha-galactosylceramide
  •  go-up   go-down


66. Crazzolara R, Bendall L: Emerging treatments in acute lymphoblastic leukemia. Curr Cancer Drug Targets; 2009 Feb;9(1):19-31
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging treatments in acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is a clonal proliferation of early B- and T-lymphocyte progenitors and results in the accumulation of leukemic blasts in the bone marrow and various extramedullary sites.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200049.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 136
  •  go-up   go-down


67. Horinouchi M, Yagi M, Imanishi H, Mori T, Yanai T, Hayakawa A, Takeshima Y, Hijioka M, Okamura N, Sakaeda T, Matsuo M, Okumura K, Nakamura T: Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatr Hematol Oncol; 2010 Aug;27(5):344-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma.
  • The objective of this study was to identify novel pharmacogenetic determinants of treatment-related hepatotoxicity during the maintenance phase in children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).
  • [MeSH-major] Drug-Induced Liver Injury / genetics. Genetic Association Studies. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


68. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P: Hodgkin lymphoma as second malignancy during continuing chemotherapy for childhood acute lymphoblastic leukemia. Klin Padiatr; 2008 Nov-Dec;220(6):388-90
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma as second malignancy during continuing chemotherapy for childhood acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is the most prevalent childhood malignancy in most parts of the world with a 5-year survival rate above 70%.
  • Hodgkin lymphoma (HL) as a complication of ALL is very rare.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / chemically induced. Neoplasms, Second Primary / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


69. Bhatia S, Kaul D, Varma N: Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia. Mol Cell Biochem; 2010 Jul;340(1-2):97-106
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia.
  • Keeping in view the fact that genes coding microRNAs (miRNAs) have been found to be localized in chromosomal regions susceptible to genetic translocations, this study was addressed to identify and characterize the miRNAs that are present near/within the regions involved in genetic translocations characteristic of B-cell acute lymphoblastic leukemia (B-cell ALL).
  • [MeSH-major] Gene Expression Regulation, Leukemic. Genes, Tumor Suppressor. MicroRNAs / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 Oct 9;25(46):6188-96 [17028598.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):167-9 [14695998.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3707-21 [11054444.001]
  • [Cites] Oncogene. 2008 Oct 6;27(45):5959-74 [18836476.001]
  • [Cites] Eur J Immunol. 1999 Nov;29(11):3745-53 [10556831.001]
  • [Cites] Chin Med J (Engl). 2000 Nov;113(11):985-90 [11776132.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3314-22 [19188669.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] Mol Cell Biochem. 2009 Mar;323(1-2):143-8 [19082544.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Semin Cancer Biol. 2003 Aug;13(4):253-8 [14563119.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1095-105 [18323801.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9762-70 [17942906.001]
  • [Cites] Leukemia. 2009 Feb;23(2):313-22 [18923441.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Semin Cancer Biol. 2008 Apr;18(2):103-10 [18295504.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6202-10 [17028600.001]
  • [Cites] Mol Cell Biochem. 2007 Mar;297(1-2):215-20 [17006618.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1115-29 [12695333.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Sep;66(3):407-25, table of contents [12208997.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e363 [15502875.001]
  • [Cites] Cell Cycle. 2007 Sep 1;6(17):2127-32 [17786041.001]
  • [Cites] Cell. 1993 Dec 3;75(5):855-62 [8252622.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(10):1529-44 [17531469.001]
  • [Cites] Br J Surg. 2007 Jan;94(1):23-30 [17205498.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):826-30 [10029071.001]
  • (PMID = 20549547.001).
  • [ISSN] 1573-4919
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AATF protein, human; 0 / Apoptosis Regulatory Proteins; 0 / MIRN196 microRNA, human; 0 / MYC protein, human; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / Repressor Proteins; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


70. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N, Byrd JC: FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood; 2008 Jan 1;111(1):275-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
  • We demonstrate here that FTY720 mediates toxic effects in cell lines representing different B-cell malignancies and primary B cells from patients with chronic lymphocytic leukemia (CLL).
  • Further, FTY720 treatment resulted in significant prolonged survival in a xenograft severe combined immunodeficiency (SCID) mouse model of disseminated B-cell lymphoma/leukemia.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 May 15;19(10):2237-46 [10811615.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):29-34 [10617581.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1289-97 [11222372.001]
  • [Cites] Transplant Proc. 2001 Feb-Mar;33(1-2):530-1 [11266942.001]
  • [Cites] Jpn J Cancer Res. 2001 Jun;92(6):680-7 [11429058.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1985 [11535540.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1410-9 [11888913.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):1073-83 [11912269.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2969-76 [11929788.001]
  • [Cites] Br J Pharmacol. 2002 Dec;137(7):953-62 [12429567.001]
  • [Cites] Br J Pharmacol. 2003 Apr;138(7):1303-12 [12711631.001]
  • [Cites] Am J Transplant. 2003 Jul;3(7):846-54 [12814476.001]
  • [Cites] Transplantation. 2003 Oct 15;76(7):1079-84 [14557756.001]
  • [Cites] J Clin Apher. 2003;18(3):141-52 [14569608.001]
  • [Cites] FEBS Lett. 2003 Nov 6;554(1-2):189-93 [14596938.001]
  • [Cites] J Org Chem. 2004 May 28;69(11):3950-2 [15153030.001]
  • [Cites] Am J Transplant. 2004 Jul;4(7):1019-25 [15196057.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4185-91 [15217956.001]
  • [Cites] Blood. 1993 Feb 15;81(4):1025-31 [8427984.001]
  • [Cites] Leuk Res. 1994 Jul;18(7):513-22 [8022201.001]
  • [Cites] Transplantation. 1996 Jan 27;61(2):200-5 [8600623.001]
  • [Cites] J Immunol. 1996 Apr 1;156(7):2624-30 [8786328.001]
  • [Cites] Oncogene. 1996 Mar 7;12(5):1055-62 [8649796.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Transplant Proc. 1996 Jun;28(3):1375-6 [8658701.001]
  • [Cites] Transplant Proc. 1996 Aug;28(4):2049-50 [8769151.001]
  • [Cites] Transpl Immunol. 1996 Sep;4(3):252-5 [8893458.001]
  • [Cites] Blood. 1997 May 1;89(9):3378-84 [9129045.001]
  • [Cites] Blood. 1998 May 1;91(9):3379-89 [9558396.001]
  • [Cites] Yonsei Med J. 2004 Dec 31;45(6):991-7 [15627289.001]
  • [Cites] Carcinogenesis. 2005 Mar;26(3):681-7 [15604094.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):182-92 [15733213.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2504-9 [15454489.001]
  • [Cites] Immunology. 2005 Apr;114(4):441-9 [15804279.001]
  • [Cites] Transplantation. 2005 Jun 15;79(11):1553-60 [15940045.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7478-84 [16103102.001]
  • [Cites] J Clin Pharmacol. 2005 Nov;45(11):1268-78 [16239360.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8458-66 [16322309.001]
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):36-47 [16473668.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2144-50 [17404098.001]
  • [Cites] Leukemia. 1999 Nov;13(11):1873-80 [10557065.001]
  • [Cites] Immunopharmacology. 2000 Jun;48(1):75-85 [10822091.001]
  • (PMID = 17761520.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA095426; United States / NCI NIH HHS / CA / R01 CA095512; United States / NCI NIH HHS / CA / CA095512; United States / NCI NIH HHS / CA / P01 CA95426
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Lysophospholipids; 0 / Mcl1 protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Propylene Glycols; 0 / Proto-Oncogene Proteins c-bcl-2; 26993-30-6 / sphingosine 1-phosphate; EC 3.1.3.16 / Protein Phosphatase 2; EC 3.4.22.- / Caspases; EC 3.4.22.- / Cysteine Endopeptidases; G926EC510T / Fingolimod Hydrochloride; NGZ37HRE42 / Sphingosine
  • [Other-IDs] NLM/ PMC2200813
  •  go-up   go-down


71. Malhotra P, Menon MC, Varma N, Mishra B, Saikia UN, Suri V, Varma S: Cytomegalovirus pneumonia in adult acute lymphoblastic leukemia. J Assoc Physicians India; 2008 Jul;56:541-2
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomegalovirus pneumonia in adult acute lymphoblastic leukemia.
  • Though acute lymphoblastic leukemia (ALL) is an immunosuppressed state, CMV disease has been reported infrequently.
  • [MeSH-major] Cytomegalovirus Infections / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846908.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antiviral Agents; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


72. Weng AP, Lau A: Notch signaling in T-cell acute lymphoblastic leukemia. Future Oncol; 2005 Aug;1(4):511-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling in T-cell acute lymphoblastic leukemia.
  • T-cell acute lymphoblastic leukemia (T-ALL) is a form of pediatric leukemia that is thought to be caused by approximately 12 distinct chromosomal translocations that lead to aberrant expression of as many different cellular genes.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / genetics. Receptors, Notch / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556027.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Notch
  • [Number-of-references] 118
  •  go-up   go-down


73. Crazzolara R, Bradstock KF, Bendall LJ: RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy; 2009 Jul;5(5):727-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia.
  • The elimination of tumor cells by apoptosis is the main mechanism of action of chemotherapeutic drugs used in current treatment protocols of acute lymphoblastic leukemia (ALL).
  • The discovery of alternative pathways involved in cell death execution and the role that it plays in leukemia suggest mTOR inhibitors should be included in future chemotherapy protocols of ALL.
  • [MeSH-major] Autophagy / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Sirolimus / analogs & derivatives


74. Abdallah E, Hajji Z, Mellal Z, Belmekki M, Bencherifa F, Berraho A: [Macular serous detachment revealing acute lymphoblastic leukemia]. J Fr Ophtalmol; 2005 Jan;28(1):39-44
MedlinePlus Health Information. consumer health - Retinal Detachment.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Macular serous detachment revealing acute lymphoblastic leukemia].
  • [Transliterated title] Décollement séreux maculaire révélateur d'une leucémie aiguë lymphoblastique.
  • The investigations showed the diagnosis of acute lymphoblastic leukemia.
  • DISCUSSION: Ocular involvement is seen in 28%-80% of leukemia cases.
  • CONCLUSION: Ocular manifestations of leukemia are frequent but rarely reveal the disease.
  • However, the diagnosis of leukemia should be considered in case of pigmentary epithelium involvement.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Detachment / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767897.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


75. Pan Y, Li GD, Liu WP, Zhang WY, Tang Y, Li FY: [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients]. Zhonghua Bing Li Xue Za Zhi; 2009 Dec;38(12):810-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
  • OBJECTIVE: To study the clinicopathologic features, immunohistochemical findings and prognosis of precursor lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL).
  • The cases were categorized into three groups according to the immunohistochemical findings, as follows: precursor T-cell, precursor B-cell and undefined.
  • CONCLUSIONS: Both TdT and CD99 are useful markers for the diagnosis of precursor lymphoblastic malignancy.
  • [MeSH-major] Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. DNA Nucleotidylexotransferase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology


76. Cohen MH, Johnson JR, Justice R, Pazdur R: FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist; 2008 Jun;13(6):709-14
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
  • Food and Drug Administration (FDA) approval of nelarabine (Arranon), a new purine analogue, for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Drug Approval / legislation & jurisprudence. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586926.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  •  go-up   go-down


77. Collins-Underwood JR, Mullighan CG: Genomic profiling of high-risk acute lymphoblastic leukemia. Leukemia; 2010 Oct;24(10):1676-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling of high-risk acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is a heterogeneous disease comprising multiple subtypes with different genetic alterations and responses to therapy.
  • Notably, genetic alteration of the lymphoid transcription factor gene IKZF1 is a hallmark of multiple subtypes of ALL with poor prognosis, including BCR-ABL1-positive lymphoid leukemia and a subset of 'BCR-ABL1-like' ALL cases that, in addition to IKZF1 alteration, harbor genetic mutations resulting in aberrant lymphoid cytokine receptor signaling, including activating mutations of Janus kinases and rearrangement of cytokine receptor-like factor 2 (CRLF2).
  • [MeSH-major] Biomarkers, Tumor / genetics. Gene Expression Profiling. Genome, Human. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20739952.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Wehrli LA, Braun J, Buetti LN, Hagleitner N, Hengartner H, Kühne T, Lüer S, Ozsahin H, Popovic MB, Niggli FK, Betts DR, Bourquin JP: Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2009 Feb;189(1):29-36
Genetic Alliance. consumer health - Acute Non Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia.
  • Karyotype analysis of acute lymphoblastic leukemia (ALL) at diagnosis has provided valuable prognostic markers for treatment stratification.
  • We compared the karyotypes from 436 nonselected B-cell precursor ALL patients at initial diagnosis and of 76 patients at first relapse.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics


79. Imai K, Akiyama H: [Acute lymphoblastic leukemia (ALL)]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2180-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia (ALL)].
  • In the past few decades, the results of treatment for childhood acute lymphoblastic leukemia (ALL) have achieved about 80% long-term disease-free survival (DFS).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079617.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down


80. Pieters R: Infant acute lymphoblastic leukemia: Lessons learned and future directions. Curr Hematol Malig Rep; 2009 Jul;4(3):167-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infant acute lymphoblastic leukemia: Lessons learned and future directions.
  • Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia.
  • [MeSH-major] Gene Rearrangement. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Oct 1;110(7):2774-5 [17881645.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):229-33 [9628434.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2023-6 [8609712.001]
  • [Cites] Med Pediatr Oncol. 1995 Mar;24(3):154-9 [7838036.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):173-83 [12620411.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1209-17 [10438708.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;39(1-2):42-50 [8995498.001]
  • [Cites] Leukemia. 2007 Apr;21(4):633-41 [17268512.001]
  • [Cites] Blood. 2005 Jan 15;105(2):812-20 [15374878.001]
  • [Cites] Br J Haematol. 2002 May;117(2):306-14 [11972512.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):35-42 [9065717.001]
  • [Cites] Blood. 2006 Jul 15;108(2):441-51 [16556894.001]
  • [Cites] Leukemia. 2004 Jan;18(1):78-83 [14574327.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):240-50 [17658395.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1859-65 [10223582.001]
  • [Cites] Leukemia. 2004 Mar;18(3):521-9 [14712291.001]
  • [Cites] Blood. 2000 Jul 1;96(1):24-33 [10891426.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):445-55 [10080584.001]
  • [Cites] Leukemia. 2009 Feb;23(2):313-22 [18923441.001]
  • [Cites] Br J Cancer Suppl. 1992 Aug;18:S23-9 [1503923.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1270-6 [12406912.001]
  • [Cites] Leukemia. 1994 Aug;8(8):1275-9 [8057661.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):650-65 [12951584.001]
  • [Cites] Blood. 1995 Feb 15;85(4):873-8 [7849309.001]
  • [Cites] Leukemia. 2006 Jan;20(1):179-82 [16307022.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2484-90 [15956279.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):847-53 [17136402.001]
  • [Cites] J Clin Invest. 1996 Feb 1;97(3):755-60 [8609232.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1073-9 [19212338.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2107-13 [10602437.001]
  • [Cites] Leukemia. 1998 Oct;12 (10 ):1561-4 [9766500.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2285-95 [9404706.001]
  • [Cites] Pediatr Blood Cancer. 2009 May;52(5):596-601 [19132729.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1344-8 [9737681.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1898-909 [9731046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8603-8 [15941828.001]
  • [Cites] Br J Haematol. 1994 Feb;86(2):284-90 [8199016.001]
  • [Cites] Cancer Treat Rep. 1977 Nov;61(8):1419-25 [579164.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Haematologica. 2006 Apr;91(4):534-7 [16537119.001]
  • [Cites] Leukemia. 2006 Feb;20(2):264-71 [16357833.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2258-63 [17690691.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):823-33 [17957188.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):539-51 [16445826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1909-15 [12057554.001]
  • (PMID = 20425430.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  • [Number-of-references] 52
  •  go-up   go-down


81. Rainer J, Ploner C, Jesacher S, Ploner A, Eduardoff M, Mansha M, Wasim M, Panzer-Grümayer R, Trajanoski Z, Niederegger H, Kofler R: Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. Leukemia; 2009 Apr;23(4):746-52
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia.
  • Glucocorticoids (GCs) induce apoptosis in lymphoid lineage cells and are therefore used in the therapy of acute lymphoblastic leukemia (ALL) and related malignancies.
  • We investigated miRNA/mirtron expression and GC regulation in 8 leukemia/lymphoma in vitro models and 13 ALL children undergoing systemic GC monotherapy using a combination of expression profiling techniques, real time reverse transcription (RT)-PCR and northern blotting to detect mature miRNAs and/or their precursors.
  • [MeSH-major] Gene Expression Regulation, Leukemic / drug effects. Glucocorticoids / pharmacology. MicroRNAs / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148136.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18571; Austria / Austrian Science Fund FWF / / P 18747
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / MIRN15 microRNA, human; 0 / MIRN16 microRNA, human; 0 / MIRN223 microRNA, human; 0 / MicroRNAs; 0 / RNA, Messenger; EC 2.7.7.- / DNA Polymerase II
  •  go-up   go-down


82. Kang W, Hahn JS, Kim JS, Cheong JW, Yang WI: Nine-year survival of lymphoblastic lymphoma patients. Yonsei Med J; 2006 Aug 31;47(4):466-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nine-year survival of lymphoblastic lymphoma patients.
  • This study aimed to analyze the overall survival period of adult lymphoblastic lymphoma patients treated with various therapeutic regimens, and to assess the determinants affecting survival outcome.
  • Twenty-five adult patients with lymphoblastic lymphoma who had been treated at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea from June 1996 to June 2005 were analyzed retrospectively.
  • The Stanford/NCOG regimen is an effective initial choice of therapy for lymphoblastic lymphoma patients, and is superior to the hyper-CVAD regimen in complete response rate and overall survival rate (p =0.36).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Rev. 2000 Mar;14(1):1-13 [10805257.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2927-36 [11387366.001]
  • [Cites] Ann Hematol. 2001 Nov;80(11):647-52 [11757723.001]
  • [Cites] Cytotherapy. 2002;4(3):223-40 [12194719.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Yonsei Med J. 1997 Oct;38(5):270-84 [9409190.001]
  • [Cites] Yonsei Med J. 2003 Oct 30;44(5):757-70 [14584090.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Semin Oncol. 1990 Feb;17(1):96-103 [2406921.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2220-4 [14576732.001]
  • (PMID = 16941734.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2687725
  •  go-up   go-down


83. Trehan A, Cheetham T, Bailey S: Hypercalcemia in acute lymphoblastic leukemia: an overview. J Pediatr Hematol Oncol; 2009 Jun;31(6):424-7
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypercalcemia in acute lymphoblastic leukemia: an overview.
  • It is an uncommon albeit well recognized biochemical feature of childhood malignancies including acute leukemia.
  • Most of the children presenting with acute lymphoblastic leukemia and hypercalcemia tend to be in older age groups and have an absence of blasts in the peripheral blood film.
  • [MeSH-major] Hypercalcemia / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648791.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


84. Kühnl A, Gökbuget N, Stroux A, Burmeister T, Neumann M, Heesch S, Haferlach T, Hoelzer D, Hofmann WK, Thiel E, Baldus CD: High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood; 2010 May 6;115(18):3737-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia.
  • Overexpression of BAALC is an adverse prognostic factor in adults with cytogenetically normal acute myeloid leukemia and T-cell acute lymphoblastic leukemia (ALL).
  • Here, we analyzed the prognostic significance of BAALC in B-precursor ALL.
  • BAALC MRNA expression was determined in 368 primary adult B-precursor ALL patients enrolled on the 06/99 and 07/03 GMALL trials.
  • Determination of BAALC might contribute to risk assessment of molecularly undefined adult B-precursor ALL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Drug Resistance, Neoplasm. Neoplasm Proteins / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 May 6;115(18):3649-50 [20448115.001]
  • (PMID = 20065290.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BAALC protein, human; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


85. Styczynski J, Kurylak A, Wysocki M: Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia. Anticancer Res; 2005 May-Jun;25(3B):2253-8
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia.
  • BACKGROUND: Glucocorticoids are the most important group of drugs used in the treatment of childhood acute lymphoblastic leukemia (ALL), however, resistance to this group remains the main obstacle in curing the disease.
  • AIM: Analysis of ex vivo sensitivity to cortivazol and other glucocorticoids in childhood acute lymphoblastic leukemia, as well as the relationship to anticancer therapy outcome.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pregnatrienes / pharmacology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158972.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Pregnatrienes; 9PHQ9Y1OLM / Prednisolone; YM183K0H63 / cortivazol
  •  go-up   go-down


86. Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, Catchpoole D, Chiaramonte R, Brini AT, Griffiths M, Maher ER, Zabarovsky E, Latif F: Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics; 2009 Apr 1;4(3):185-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic analysis of childhood acute lymphoblastic leukemia.
  • We used a chromosome 3 wide NotI microarray for identification of epigenetically inactivated genes in childhood acute lymphoblastic leukemia (ALL).
  • The methylation of the above five genes was cancer specific and expression of the genes could be restored in methylated leukemia cell lines treated with 5-aza-2'-deoxycytidine.
  • This is the first report demonstrating frequent epigenetic inactivation of PPP2R3A, FBLN2, THRB, BNC1 and MSX1 in leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. DNA Methylation. Epigenesis, Genetic. Gene Expression Regulation, Leukemic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


87. André JM, Galambrun C, Trzeciak MC, Dargaud Y, Kaplan-Gouet C, Jallu V, Bertrand Y: Acquired Glanzmann's thrombasthenia associated with acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2005 Oct;27(10):554-7
Genetic Alliance. consumer health - Thrombasthenia of Glanzmann and Naegeli.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired Glanzmann's thrombasthenia associated with acute lymphoblastic leukemia.
  • Acquired Glanzmann's thrombasthenia is an uncommon event in association with leukemia.
  • The authors describe a patient with acute lymphoblastic leukemia (ALL) who presented with severe hemorrhagic syndrome, without disseminated intravascular coagulation.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Thrombasthenia / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Thrombasthenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217260.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Platelet Glycoprotein GPIIb-IIIa Complex
  •  go-up   go-down


88. Bayrak IK, Yalin T, Ozmen Z, Aksoz T, Doughanji R: Acute lymphoblastic leukemia presented as multiple breast masses. Korean J Radiol; 2009 Sep-Oct;10(5):508-10
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia presented as multiple breast masses.
  • Breast metastases in cases leukemia are very rare and occur primarily in patients with acute myeloid leukemia.
  • We report the involvement of breast metastases in a 30-year-old woman with acute T cell lymphoblastic leukemia.
  • [MeSH-major] Breast Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiol Clin North Am. 1982 Sep;20(3):561-8 [7111707.001]
  • [Cites] AJR Am J Roentgenol. 1983 Oct;141(4):685-90 [6604418.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):343-8 [9930779.001]
  • [Cites] Clin Pediatr (Phila). 1999 Sep;38(9):545-6 [10500889.001]
  • [Cites] J Clin Ultrasound. 2002 Nov-Dec;30(9):552-6 [12404522.001]
  • [Cites] Semin Ultrasound CT MR. 2000 Oct;21(5):375-94 [11071618.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3993-6 [11099329.001]
  • [Cites] Radiographics. 2000 Nov-Dec;20(6):1605-12 [11112814.001]
  • [Cites] Eur Radiol. 2000;10(6):1031 [10879725.001]
  • (PMID = 19721836.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 10
  • [Other-IDs] NLM/ PMC2731869
  • [Keywords] NOTNLM ; Acute lymphoblastic leukemia / Breast metastasis / Mammography / Ultrasonography
  •  go-up   go-down


89. Shimasaki N, Mori T, Torii C, Sato R, Shimada H, Tanigawara Y, Kosaki K, Takahashi T: Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol; 2008 May;30(5):347-52
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
  • We investigated preliminarily whether methylenetetrahydrofolate reductase (MTHFR) 677C/T or reduced folate carrier 1 (RFC1) 80G/A polymorphisms were associated with toxicities during maintenance chemotherapy with mercaptopurine (6MP) and methotrexate (MTX) in children with acute lymphoblastic leukemia or lymphoblastic lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carbon-Nitrogen Ligases / genetics. Polymorphism, Genetic. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Reduced Folate Carrier Protein / genetics


90. Vitale A, Guarini A, Chiaretti S, Foà R: The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol; 2006 Nov;18(6):652-9
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing scene of adult acute lymphoblastic leukemia.
  • PURPOSE OF REVIEW: The review focuses on the most recent advances in the diagnostic and prognostic work-up of adult acute lymphoblastic leukemia (ALL) and its implications in the clinical management of the disease.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988590.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 104
  •  go-up   go-down


91. Kurosawa H, Matsunaga T, Shimura N, Nakajima D, Hagisawa S, Fukushima K, Sugita K, Phyo K, Arisaka O: Successfully treated acute lymphoblastic leukemia associated with craniopharyngioma. J Pediatr Hematol Oncol; 2007 Jun;29(6):416-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successfully treated acute lymphoblastic leukemia associated with craniopharyngioma.
  • The authors report a 2-year-old boy with acute lymphoblastic leukemia (ALL) associated with craniopharyngioma.
  • At 4 years after completing leukemia chemotherapy, the patient remains in complete ALL remission and has had no recurrence of craniopharyngioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Craniopharyngioma / drug therapy. Pituitary Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551406.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Harned TM, Gaynon P: Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep; 2008 Nov;10(6):453-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsed acute lymphoblastic leukemia: current status and future opportunities.
  • Significant improvements in primary therapy for childhood acute lymphoblastic leukemia (ALL) have led to dramatic increases in cure rates over the past few decades.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pharmacother. 2005 Jun;39(6):1056-63 [15870141.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2826-32 [17099879.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2321-32 [9404710.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;4(5):369-70 [15902772.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):1-2 [17325839.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1043-50 [17640858.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2057-66 [17536015.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):233-9 [9473758.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5800-7 [18089878.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):361-8 [15723262.001]
  • [Cites] Leukemia. 2003 Oct;17(10):1967-72 [14513046.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):13-23 [16292537.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53 [17069520.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):68-72 [9065722.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(2):133-9 [17994118.001]
  • [Cites] Leukemia. 2008 Feb;22(2):281-6 [18033318.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • (PMID = 18928659.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 44
  •  go-up   go-down


93. Karremann M, von Komorowski G, Neumaier-Probst E, Dürken M: [Hemiparesis in acute lymphoblastic leukemia]. Radiologe; 2010 Aug;50(8):706-10
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemiparesis in acute lymphoblastic leukemia].
  • The case of an adolescent female patient with acute lymphoblastic leukemia and stroke-like hemiparesis demonstrates a typical manifestation of methotrexate-induced acute encephalopathy.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Methotrexate / adverse effects. Neurotoxicity Syndromes / diagnosis. Paresis / chemically induced. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2007 Feb;21(2):238-47 [17170721.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1688-95 [15569732.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):373-7 [17522329.001]
  • [Cites] Pediatr Radiol. 2006 Mar;36(3):205-12 [16369780.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):178-84 [17947226.001]
  • (PMID = 20652214.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


94. Podgornik H, Debeljak M, Zontar D, Cernelc P, Prestor VV, Jazbec J: RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia. Cancer Genet Cytogenet; 2007 Oct 1;178(1):77-81
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia.
  • Amplification of RUNX1 (alias AML1) is a recurrent karyotypic abnormality in childhood acute lymphoblastic leukemia (ALL) that is generally associated with a poor outcome.
  • AML1 amplification in acute myelogenous leukemia (AML) is a rare secondary event described mainly in therapy-related cases.
  • AML1 amplification was found in a 13-year-old patient with AML M4/M5 leukemia that occurred 5 years after she had been diagnosed with common B-cell ALL.
  • Conventional cytogenetic, fluorescent in situ hybridization (FISH), and polymerase chain reaction methods revealed no other chromosomal change expected to occur in a disease that we assumed to be a secondary leukemia.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Regulation, Neoplastic. Leukemia, B-Cell / genetics. Leukemia, B-Cell / pathology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


95. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M, Okumura K: Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet; 2007;52(2):166-71
Nature Publishing Group. Nature Publishing Group (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.
  • Methotrexate is administered in high doses to treat childhood acute lymphoblastic leukemia and malignant lymphoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Liver Diseases / genetics. Lymphoma / genetics. Methotrexate / therapeutic use. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


96. Stock W: Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2010;2010:21-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adolescents and young adults with acute lymphoblastic leukemia.
  • During the last decade, increasing attention has been paid to a unique group of patients with acute lymphoblastic leukemia (ALL) who lie at the crossroad of therapeutic care by pediatric and adult hematologists/oncologists.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21239766.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


97. Litten JB, Rodríguez MM, Maniaci V: Acute lymphoblastic leukemia presenting in fulminant hepatic failure. Pediatr Blood Cancer; 2006 Nov;47(6):842-5
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia presenting in fulminant hepatic failure.
  • Bone marrow aspiration confirmed the diagnosis of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Liver Failure, Acute / etiology. Liver Failure, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16106432.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M: SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells. Oncogene; 2006 Aug 24;25(37):5180-6
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells.
  • Perpetual V(D)J recombinase activity involving multiple DNA double-strand break events in B-cell lineage leukemia and lymphoma cells may introduce secondary genetic aberrations leading towards malignant progression.
  • On studying 28 cases of pre-B-lymphoblastic leukemia and 27 B-cell lymphomas, expression of the (pre-) B-cell receptor-related linker molecule SLP65 (SH2 domain-containing lymphocyte protein of 65 kDa) was found to be defective in seven and five cases, respectively.
  • Reconstitution of SLP65 expression in SLP65-deficient leukemia and lymphoma cells results in downregulation of RAG1/2 expression and prevents both de novo V(H)-DJ(H) rearrangements and secondary V(H) replacement.
  • [MeSH-major] Burkitt Lymphoma / genetics. Carrier Proteins / genetics. Lymphoma, B-Cell / genetics. Phosphoproteins / deficiency. Phosphoproteins / genetics. VDJ Recombinases / metabolism

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636677.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / B cell linker protein; 0 / Carrier Proteins; 0 / Phosphoproteins; EC 2.7.7.- / VDJ Recombinases
  •  go-up   go-down


99. DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA: Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood; 2007 Jun 15;109(12):5136-42
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
  • We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1984 Sep;74(3):951-5 [6332120.001]
  • [Cites] Blood. 1983 Apr;61(4):660-6 [6600944.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3646-50 [2410098.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6498-502 [2819707.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Transplantation. 1991 Oct;52(4):634-40 [1926342.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3352-6 [7614470.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):70-82 [9045306.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):896-903 [9217194.001]
  • [Cites] Adv Exp Med Biol. 1984;165 Pt B:309-14 [6609537.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):671-7 [9401083.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1216-30 [10506707.001]
  • [Cites] Biochemistry. 1964 Jan;3:15-8 [14114497.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):995-1003 [10694549.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Biochemistry. 1981 Jun 9;20(12):3615-21 [6789872.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1008-14 [3971358.001]
  • (PMID = 17344466.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / N01 CA013612; United States / NCI NIH HHS / CA / U10 CA013612; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  • [Other-IDs] NLM/ PMC1941786
  •  go-up   go-down


100. Fullmer A, O'Brien S, Kantarjian H, Jabbour E: Novel therapies for relapsed acute lymphoblastic leukemia. Curr Hematol Malig Rep; 2009 Jul;4(3):148-56
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapies for relapsed acute lymphoblastic leukemia.
  • The outcome of salvage therapy for relapsed acute lymphoblastic leukemia (ALL) remains poor.
  • Clofarabine, a second-generation purine analogue approved in pediatric leukemia, has shown activity in adult acute leukemias including ALL and acute myeloid leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425428.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  • [Other-IDs] NLM/ NIHMS674650; NLM/ PMC4572835
  •  go-up   go-down






Advertisement